Nixon Peabody Trust’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $432K | Sell |
4,781
-1,010
| -17% | -$84.6K | 0.03% | 135 |
|
|
2026
Q1 | $464K | Sell |
5,791
-668
| -10% | -$55.1K | 0.04% | 117 |
|
|
2025
Q4 | $551K | Sell |
6,459
-622
| -9% | -$51K | 0.04% | 108 |
|
|
2025
Q3 | $551K | Sell |
7,081
-220
| -3% | -$17.2K | 0.04% | 107 |
|
|
2025
Q2 | $571K | Sell |
7,301
-47
| -0.6% | -$3.5K | 0.04% | 107 |
|
|
2025
Q1 | $533K | Sell |
7,348
-328
| -4% | -$23.5K | 0.05% | 110 |
|
|
2024
Q4 | $568K | Buy |
7,676
+29
| +0.4% | +$2.03K | 0.05% | 95 |
|
|
2024
Q3 | $505K | Sell |
7,647
-550
| -7% | -$40K | 0.04% | 98 |
|
|
2024
Q2 | $757K | Sell |
8,197
-733
| -8% | -$64.9K | 0.07% | 79 |
|
|
2024
Q1 | $853K | Buy |
8,930
+495
| +6% | +$41.6K | 0.08% | 74 |
|
|
2023
Q4 | $643K | Buy |
+8,435
| New | +$587K | 0.07% | 76 |
|
|
2022
Q1 | – | Sell |
-7,806
| Closed | -$1.01M | – | 84 |
|
|
2021
Q4 | $1.01M | Buy |
+7,806
| New | +$911K | 0.31% | 55 |
|
|
2021
Q3 | – | Sell |
-1,934
| Closed | -$200K | – | 72 |
|
|
2021
Q2 | $200K | Buy |
+1,934
| New | +$182K | 0.08% | 68 |
|
|
2021
Q1 | – | Sell |
-2,226
| Closed | -$203K | – | 71 |
|
|
2020
Q4 | $203K | Buy |
+2,226
| New | +$185K | 0.09% | 69 |
|
|
2020
Q1 | – | Sell |
-3,147
| Closed | -$245K | – | 78 |
|
|
2019
Q4 | $245K | Sell |
3,147
-105
| -3% | -$8.2K | 0.12% | 72 |
|
|
2019
Q3 | $238K | Sell |
3,252
-1,509
| -32% | -$106K | 0.13% | 70 |
|
|
2019
Q2 | $293K | Sell |
4,761
-1,335
| -22% | -$80.7K | 0.17% | 67 |
|
|
2019
Q1 | $389K | Sell |
6,096
-1,839
| -23% | -$105K | 0.25% | 62 |
|
|
2018
Q4 | $405K | Sell |
7,935
-840
| -10% | -$42.5K | 0.32% | 61 |
|
|
2018
Q3 | $509K | Sell |
8,775
-5,475
| -38% | -$268K | 0.35% | 61 |
|
|
2018
Q2 | $691K | Sell |
14,250
-5,415
| -28% | -$253K | 0.54% | 56 |
|
|
2018
Q1 | $915K | Sell |
19,665
-5,235
| -21% | -$227K | 0.82% | 46 |
|
|
2017
Q4 | $936K | Sell |
24,900
-555
| -2% | -$20.4K | 0.81% | 44 |
|
|
2017
Q3 | $927K | Sell |
25,455
-4,125
| -14% | -$157K | 0.84% | 44 |
|
|
2017
Q2 | $1.17M | Sell |
29,580
-4,290
| -13% | -$157K | 1.08% | 39 |
|
|
2017
Q1 | $1.06M | Sell |
33,870
-3,960
| -10% | -$124K | 1% | 40 |
|
|
2016
Q4 | $1.18M | Sell |
37,830
-2,220
| -6% | -$71.9K | 1.15% | 39 |
|
|
2016
Q3 | $1.61M | Sell |
40,050
-7,440
| -16% | -$280K | 1.58% | 31 |
|
|
2016
Q2 | $1.58M | Sell |
47,490
-9,885
| -17% | -$338K | 1.37% | 29 |
|
|
2016
Q1 | $1.69M | Sell |
57,375
-1,545
| -3% | -$42.6K | 1.5% | 25 |
|
|
2015
Q4 | $1.55M | Buy |
+58,920
| New | +$1.53M | 1.41% | 23 |
|
Other funds holding EW
WT
BHIA
NONA
SIM
AAIS
Nixon Peabody Trust's EW Position: Q2 2026 in Review
Nixon Peabody Trust reduced its Edwards Lifesciences (EW) stake by 17% in Q2 2026, selling an estimated $84.6K and leaving 4,781 shares worth $432K. The position accounts for 0.03% of the portfolio, ranked #135.
Nixon Peabody Trust first reported a position in EW in Q4 2015 and has held it in 31 quarters since. The position peaked at $1.69M in Q1 2016. 458 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Nixon Peabody Trust held 4,781 shares of Edwards Lifesciences worth $432K as of Q2 2026.
- Nixon Peabody Trust sold 1,010 Edwards Lifesciences shares in Q2 2026, an estimated $84.6K.
- Edwards Lifesciences made up 0.03% of Nixon Peabody Trust's portfolio in Q2 2026, its #135 holding.
- Nixon Peabody Trust first reported a position in Edwards Lifesciences in Q4 2015 and has held it in 31 quarters since.
- Nixon Peabody Trust's Edwards Lifesciences position peaked at $1.69M in Q1 2016.
- 458 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Nixon Peabody Trust's 13F filing for Q2 2026, filed 27 Jul 2026.